Connect with us

Hi, what are you looking for?


Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant

DURHAM, N.C. and BEIJING, Dec. 12, 2021 /PRNewswire/ — Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced…


Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like